CCA
ORTX

Catalyst Capital Advisors’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Catalyst Capital Advisors’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-46
Closed -$7K – 492
2018
Q4 		$7K Buy
+46
New +$6.86K ﹤0.01% 335

Other funds holding ORTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Catalyst Capital Advisors's ORTX Position: Q1 2019 in Review

Catalyst Capital Advisors sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2019, closing a stake of 46 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in ORTX in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 43 funds tracked by Wall St. Rank hold ORTX as of Q1 2019.

  • Catalyst Capital Advisors reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 46 Orchard Therapeutics plc American Depositary Shares shares in Q1 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Orchard Therapeutics plc American Depositary Shares position peaked at $7K in Q4 2018.
  • 43 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2019.

Based on Catalyst Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.